RIA (Research and Innovation Action)

Funded by the Innovative Medicines Initiative (IMI) 2 Project

01/10/2021 – 30/09/2026 (5 years)

Stichting European Urological Foundation


Stichting European Urological Foundation, Netherlands

Lunds Universitet, Sweden

Erasmus Universitair Medisch Centrum Rotterdam, Netherlands

Association EISBM, France

The University Court of The University Of Aberdeen, United Kingdom

Tartu Ulikool, Estonia

Universita Vitasalute San Raffaele, Italy

Queen Mary University of London, United Kingdom

Helmholtzzentrum Dresdenrossendorf EV, Germany

Helios Klinikum Emil Von Behring GMBH, Germany

Uppsala Universitet, Sweden

The Chancellor, Masters And Scholars Of The University Of Oxford, United Kingdom

Universitat Wien, Austria

Istituto Europeo Di Oncologia SRL, Italy

Ludwigmaximiliansuniversitaet Muenchen, Germany

University College London, United Kingdom

European Organisation for Research and Treatment of Cancer AISBL, Belgium

Institut de Cancerologie De L’Ouest, France

Universiteit Maastricht, Netherlands

Fundacio Institut Universitari Pera La Recerca A L’atencio Primaria De Salut Jordi Gol I Gurina, Spain

European Respiratory Society, Switzerland

Deutsche Krebsgesellschaft EV, Germany

European Lung Foundation, United Kingdom

European Lung Foundation Europe, Belgium

European Cancer Patient Coalition, Belgium

TTOPSTART BV, Netherlands

GMV Soluciones Globales Internet SAU, Spain

Information Technology For Translational Medicine (ITTM) SA, Luxembourg

Smart Reporting GMBH, Germany

OWKIN France, France

Arttic Innovation GMBH, Germany

YDEAL.NET Software LDA, Portugal

Pfizer Limited, United Kingdom

Bayer Aktiengesellschaft, Germany

AMGEN, Belgium

F. Hoffmann-La Roche AG, Switzerland

ABBVIE INC, United States

Why it matters

Following the experience with the predecessor (PIONEER) project, OPTIMA intends to extend its goals to other two cancers, breast and lung cancer. Taking PIONEER as a template and starting point, the idea of this project is to improve the integration of all the information available from patients, translate it into a standardised format, and process it through Artificial Intelligence to achieve the best ways for early diagnosis, personalised therapy.

What ECPC does

ECPC is contributing to the overall project by providing a voice to prostate , breast and lung cancer patients through offering expert patient input and advice during the entire life cycle of the project. The participation of ECPC ensures that the patients engage in their disease management, thus leading to better treatment adherence and improved Quality of Life (QoL). This includes and is not limited to reviewing informed consent forms, surveys, study protocols and guidelines, setting up patient focus groups, drafting patient information leaflets and brochures, and the successful communication and dissemination of the project’s deliverables. ECPC is also working to ensure that the visual identity of PIONEER is aligned with the branding of the DO-IT communication and support action for all BD4BO projects supported by the IMI.

EU flag logo

This project has received funding from the European Union’s Horizon 2020 research and innovation
programme under grant agreement No 101034347